|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Derivation of hypermethylated pluripotent embryonic stem cells with high potency显示文摘天真的 hypomethylated 胚胎的 pluripotent 干细胞(转换字符) 离胚囊的 preimplantation epiblast 发展地最靠近,与潜力到贡献所有胚胎的纸巾和 germline,除了在妄想的胚胎的胚胎外的纸巾。由对比,类似于 postimplantation epiblast 的 epiblast 干细胞(EpiSCs ) 是相对更多的 methylated 和表演为 chimerism 的一个有限潜力。第一次,这里,我们在 pluripotent 房间以外发展地揭示先进 pluripotent 干细胞(ASC ) ,它是在内部房间团中,但是与更高的力量比 EpiSCs。因此,单个 ASC 在怪物很高效地作出贡献到胎儿, germline,蛋黄囊和胎盘的迷宫。因为他们是,发展地,更多进展了, ASC 不贡献 trophoblast。ASC 在与 Activin A 和基本成纤维细胞生长因素补充的化学上定义的媒介在二个步骤从胚囊被导出,在包含 ActA, BMP4, CHIR99021 和白血病的 ABCL 媒介由 culturing 列在后面禁止的因素。尤其是, ASC 与天真的 pluripotency 基因,以及 mesodermal 的表示展出不同 transcriptome 体的基因;Eomes,时代, Tdgf1, Evx1, hand1, Wnt5a 和不同重复元素。到 ASC 的确定的转换字符的变换也是可完成的。重要地, ASC 作为与 hypomethylated 相比展出稳定的 hypermethylated epigenome 和主要未经触动的印记胚囊和天真的转换字符的内部房间质量。ASC 的性质建议他们以在 pluripotency 的天真、告知的状态之间的一个中间的细胞的状态代表房间。 | Siqin Bao Walfred WC Tang Baojiang Wu Shinseog Kim Jingyun Li Lin Li Toshihiro Kobayashi Caroline Lee Yanglin Chen Mengyi Wei Shudong Li Sabine Dietmann Fuchou Tang Xihe Li | 2018 | Cell Research2018，28，1： | 4 |
| 2 | In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures显示文摘 | Chao Ni Yuhui Chen Musheng Zeng Rongjuan Pei Yong Du Linquan Tang Mengyi Wang Yazhuo Hu Hanyu Zhu Meifang He Xiawei Wei Shan Wang Xiangkai Ning Manna Wang Jufang Wang Li Ma Xinwen Chen Qiang Sun Hong Tang Ying Wang Xiaoning Wang | 2015 | Cell Research2015，25，7： | 3 |
| 3 | Clinical practice guideline for body composition assessment based on upper abdominal magnetic resonance images annotated using artificial intelligence显示文摘Introduction Upper abdominal magnetic resonance(MR)imaging is appropriate for body composition analysis.111 Especially for individuals with obesity,it is of great value to quantify the hepatic proton density fat fraction(PDFF)and the amount of abdominal adipose tissue during clinical evaluation and for research on obesity-related risks.Analytical results may be used to determine the optimal choice of surgical procedure and evaluate treatment outcomes.Multiple artificial intelligence(Al)algorithms and systems have been developed for the automated measurement of body composition.The basis of Al development and application is to have uniform standards for clinical data acquisition and management.The uneven quality ofMR images is one ofthe major obstacles to Al system development and analytical results.A standardized process of MR scanning and clinical data management is urgently needed. | Han Lv Mengyi Li Zhenchang Wang Dawei Yang Hui Xu Juan Li Yang Liu Di Cao Yawen Liu Xinru Wu He Jin Peng Zhang Liqin Zhao Rixing Bai Yunlong Yue Bin Li Nengwei Zhang Mingzhu Zou Jinghai Song Weibin Yu Pin Zhang Weijun Tang Qiyuan Yao Liheng Liu Hui Yang Zhenghan Yang Zhongtao Zhang National Clinical Research Center for Digestive Diseases in Beijing Friendship Hospital,Capital Medical University Beijing Quality Control and Improvement Center of Medical Imaging National Health Commission Capacity Building and Continuing Education Center,Chinese College of Metabolic and Bariatric Surgeons Beijing Quality Control and Improvement Center of Metabolic and Bariatric Surgery | 2022 | Chinese Medical Journal2022，，6： | 1 |
| 4 | The F5 gene predicts poor prognosis of patients with gastric cancer by promoting cell migration identified using a weighted gene co-expression network analysis显示文摘Distal gastric cancer(DGC)is a subgroup of gastric cancer(GC),which has different molecular characteristics from proximal gastric cancer(PGC).These differences result in different overall survival(OS)rates;however,data pertaining to the survival rate in PGC or DGC are contradictory.This suggests that the location of GC is not the unique cause of the different survival rates,while the molecular characteristics might be more important factors determining the prognosis of DGC.Therefore,the aim of this study was to discover key prognostic factors in DGC using bioinformatic methods and to explore the potential molecular mechanism.The Cancer Genome Atlas(TCGA)public database was employed to screen data relating to DGC,and we conducted a weighted gene co-expression network analysis(WGCNA)on DGC patient samples to establish co-expression modules.High-weight genes(hub genes)in a dominant color module were identified.In vitro experiments and gene set enrichment analyses(GSEA)were carried out to elucidate the potential molecular mechanism.In this study,139 DGC samples were enrolled to perform a co-expression analysis.According to the correlation between gene modules and clinical characteristics,the royal blue module related to stage M of DGC was screened,and a survival analysis was conducted to show that highcoagulation-factor V(F5)expression was related to the short OS of patients with GC.In vitro experiments confirmed that F5 could promote the migration of GC cells.GSEA suggested that F5 might have affected the prognosis of GC by modulating the activities of the Wnt and/or the TGF-βsignaling pathways.Our results indicated that high F5 expression predicts poor prognosis of patients with DGC,and it functions probably by promoting cell migration through the Wnt and/or the TGF-βsignaling pathways. | MENGYI TANG BOWEN YANG CHUANG ZHANG CHAOXU ZHANG DAN ZANG LIBAO GONG YUNPENG LIU ZHI LI XIUJUAN QU | 2021 | BIOCELL2021，45，4： | 0 |
| 5 | Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies显示文摘Background:Chimeric antigen receptor T(CAR-T)therapy has substantially revolutionized the clinical outcomes of patients with hematologic malignan-cies,but the cancer-intrinsic mechanisms underlying resistance to CAR-T cells remain yet to be fully understood.This study aims to explore the molecular deter-minants of cancer cell sensitivity to CAR-T cell-mediated killing and to provide a better understanding of the underlying mechanisms and potential modulation to improve clinical efficacy.Methods:The human whole-genome CRISPR/Cas9-based knockout screening was conducted to identify key genes that enable cancer cells to evade CD19 CAR-T-cell-mediated killing.The in vitro cytotoxicity assays and evaluation of tumor tissue and bone marrow specimens were further conducted to confirm the role of the key genes in cancer cell susceptibility to CAR-T cells.In addition,the specific mechanisms influencing CAR-T cell-mediated cancer clearance were elucidated in mouse and cellular models.Results:The CRISPR/Cas9-based knockout screening showed that the enrich-ment of autophagy-related genes(ATG3,BECN1,and RB1CC1)provided protec-tion of cancer cells from CD19 CAR-T cell-mediated cytotoxicity.These findings were further validated by in vitro cytotoxicity assays in cells with genetic and pharmacological inhibition of autophagy.Notably,higher expression of the three autophagy-related proteins in tumor samples was correlated with poorer respon-siveness and worse survival in patients with relapsed/refractory B-cell lymphoma after CD19 CAR-T therapy.Bulk RNA sequencing analysis of bone marrow samples from B-cell leukemia patients also suggested the clinical relevance of autophagy to the therapeutic response and relapse after CD19 CAR-T cell ther-apy.Pharmacological inhibition of autophagy and knockout of RB1CC1 could dramatically sensitize tumor cells to CD19 CAR-T cell-mediated killing in mouse models of both B-cell leukemia and lymphoma.Moreover,our study revealed that cancer-intrinsic autophagy mediates evasion of CAR-T cells via the TNF-α-TNFR1 axis-mediated apoptosis and STAT1/IRF1-induced chemokine signaling activation.Conclusions:These findings confirm that autophagy signaling in B-cell malig-nancies is essential for the effective cytotoxic function of CAR-T cells and thereby pave the way for the development of autophagy-targeting strategies to improve the clinical efficacy of CAR-T cell immunotherapy. | Lu Tang Huan Zhang Fen Zhou Qiuzhe Wei Mengyi Du Jianghua Wu Chenggong Li Wenjing Luo Jie Zhou Xindi Wang Zhaozhao Chen Yinqiang Zhang Zhongpei Huang Zhuolin Wu Yuxi Wen Huiwen Jiang Danying Liao Haiming Kou Wei Xiong Heng Mei Yu Hu | 2024 | Cancer Communications2024，44，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员